You searched for: deferasirox (Engelska - Maltesiska)

exjade deferasirox
exjade deferasiross

the active substance is deferasirox.
is-sustanza attiva hi deferasirox.

description of available deferasirox formulations
deskrizzjoni tal-formulazzjonijiet disponibbli ta’ deferasirox

exjade 125 mg dispersible tablets deferasirox
exjade 125 mg pilloli li jinxterdu deferasirox

deferasirox metabolism depends on ugt enzymes.
il-metaboliżmu ta’ deferasirox jiddependi fuq l-enzimi ugt.

each dispersible tablet contains 125 mg deferasirox.
kull pillola li tinxtered fiha 125 mg deferasirox.

exjade 180 mg film-coated tablets deferasirox
exjade 180 mg pilloli miksija b’rita deferasirox

each dispersible tablet contains 125 mg of deferasirox.
kull pillola li tinxtered fiha 125 mg deferasirox.

deferasirox (used to reduce chronic iron overload)
deferasirox ( użat biex jitnaqqas l-ammont kroniku żejjed ta’ ħadid)

each film-coated tablet contains 180 mg deferasirox.
kull pillola miksija b’rita fiha 180 mg deferasirox.

each tablet of exjade 125 mg contains 125 mg deferasirox.
kull pillola exjade 125 mg fiha 125 mg deferasirox.

deferasirox promotes excretion of iron, primarily in the faeces.
deferasirox jinkuraġġixxi l-eskrezzjoni tal-ħadid, l-aktar mal-ippurgar.

each tablet contains 125 mg, 250 mg or 500 mg of deferasirox.
kull pillola fiha 125 mg, 250 mg jew 500 mg deferasirox.

deferasirox did not cause other effects on fertility or reproduction.
deferasirox ma kellux effetti oħrajn fuq il-fertilità jew fuq ir-riproduzzjoni.

what exjade is exjade contains an active substance called deferasirox.
x’ inhu exjade exjade fih sustanza attiva li jisimha deferasirox.

each film-coated tablet of exjade 180 mg contains 180 mg deferasirox.
kull pillola miksija b’rita ta’ exjade 180 mg fiha 180 mg deferasirox.

close clinical monitoring is required when deferasirox is combined with these substances.
monitoraġġ kliniku mill-qrib huwa meħtieġ meta deferasirox jiġi kkombinat ma’ dawn is-sustanzi.

an interaction between deferasirox and other cyp2c8 substrates like paclitaxel cannot be excluded.
mhux eskluż li deferasirox u substrati oħrajn ta’ cyp2c8 bħal paclitaxel ma jaqblux bejniethom.

exjade 125 mg dispersible tablets exjade 250 mg dispersible tablets exjade 500 mg dispersible tablets deferasirox
exjade 125 mg pilloli li jinxterdu exjade 250 mg pilloli li jinxterdu exjade 500 mg pilloli li jinxterdu deferasirox

there have been post-marketing reports of metabolic acidosis occurring during treatment with deferasirox.
kien hemm rapport li saru wara li l-prodott ħareġ fis-suq dwar aċidożi metabolika li seħħet matul it- trattament b’deferasirox.